Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Oncogene volume 42, pages 2629–2640 (2023)
645
2
Metrics details
A Correction to this article was published on 08 September 2023
This article has been updated
Preventing or effectively treating metastatic uveal melanoma (UM) is critical because it occurs in about half of patients and confers a very poor prognosis. There is emerging evidence that hepatocyte growth factor (HGF) and insulin-like growth factor 1 (IGF-1) promote metastasis and contribute to the striking metastatic hepatotropism observed in UM metastasis. However, the molecular mechanisms by which HGF and IGF-1 promote UM liver metastasis have not been elucidated. ASAP1, which acts as an effector for the small GTPase ARF6, is highly expressed in the subset of uveal melanomas most likely to metastasize. Here, we found that HGF and IGF-1 hyperactivate ARF6, leading to its interaction with ASAP1, which then acts as an effector to induce nuclear localization and transcriptional activity of NFAT1. Inhibition of any component of this pathway impairs cellular invasiveness. Additionally, knocking down ASAP1 or inhibiting NFAT signaling reduces metastasis in a xenograft mouse model of UM. The discovery of this signaling pathway represents not only an advancement in our understanding of the biology of uveal melanoma metastasis but also identifies a novel pathway that could be targeted to treat or prevent metastatic uveal melanoma.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 50 print issues and online access
£169.00 per year
only £3.38 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
All data that support the results of this study can be found within the main text and figures of this paper or in the Supplementary information.
A Correction to this paper has been published: https://doi.org/10.1038/s41388-023-02828-x
Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012;119:1582–9.
Article PubMed Google Scholar
Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279–89.
Article CAS PubMed PubMed Central Google Scholar
Yavuzyigitoglu S, Koopmans AE, Verdijk RM, Vaarwater J, Eussen B, van Bodegom A, et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology. 2016;123:1118–28.
Article PubMed Google Scholar
Grossniklaus HE. Understanding uveal melanoma metastasis to the liver: The Zimmerman effect and the Zimmerman hypothesis. Ophthalmology. 2019;126:483–7.
Article PubMed Google Scholar
Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30:1370–80.
Article CAS PubMed Google Scholar
Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020;22:497–505.
Article PubMed Google Scholar
Schank TE, Hassel JC. Immunotherapies for the treatment of uveal melanoma-history and future. Cancers (Basel). 2019;11:1048.
Article CAS PubMed Google Scholar
Piperno-Neumann S, Larkin J, Carvajal RD, Luke JJ, Schwartz GK, Hodi FS, et al. Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071. Mol Cancer Ther. 2020;19:1031–9.
Article CAS PubMed Google Scholar
Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:782–9.
Article CAS PubMed PubMed Central Google Scholar
Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018;36:1232–9.
Article CAS PubMed Google Scholar
Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, et al. Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat Commun. 2018;9:116.
Article PubMed PubMed Central Google Scholar
Shain AH, Bagger MM, Yu R, Chang D, Liu S, Vemula S, et al. The genetic evolution of metastatic uveal melanoma. Nat Genet. 2019;51:1123–30.
Article CAS PubMed PubMed Central Google Scholar
Rao PK, Barker C, Coit DG, Joseph RW, Materin M, Rengan R, et al. NCCN guidelines insights: uveal melanoma, version 1.2019. J Natl Compr Canc Netw. 2020;18:120–31.
PubMed Google Scholar
Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32:204–220 e215.
Article CAS PubMed PubMed Central Google Scholar
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410–3.
Article CAS PubMed PubMed Central Google Scholar
Worley LA, Onken MD, Person E, Robirds D, Branson J, Char DH, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res. 2007;13:1466–71.
Article CAS PubMed Google Scholar
Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134:728–33.
Article PubMed PubMed Central Google Scholar
Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 2020;11:496.
Article CAS PubMed PubMed Central Google Scholar
Tanaka R, Terai M, Londin E, Sato T. The role of HGF/MET signaling in metastatic uveal melanoma. Cancers (Basel). 2021;13:5457.
Article CAS PubMed Google Scholar
Oba J, Esmaeli B, Ellerhorst JA, Lyons GR, Milton DR, Wang WL, et al. Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression. Melanoma Res. 2017;27:126–33.
Article CAS PubMed Google Scholar
Yoshida M, Selvan S, McCue PA, DeAngelis T, Baserga R, Fujii A, et al. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res. 2014;27:297–308.
Article CAS PubMed Google Scholar
Frenkel S, Zloto O, Pe’er J, Barak V. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans. Invest Ophthalmol Vis Sci. 2013;54:490–3.
Article CAS PubMed Google Scholar
Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, et al. ARF6 is an actionable node that orchestrates oncogenic GNAQ signaling in uveal melanoma. Cancer Cell. 2016;29:889–904.
Article CAS PubMed PubMed Central Google Scholar
Grossmann AH, Zhao H, Jenkins N, Zhu W, Richards JR, Yoo JH, et al. The small GTPase ARF6 regulates protein trafficking to control cellular function during development and in disease. Small GTPases. 2019;10:1–12.
Article CAS PubMed Google Scholar
Hashimoto S, Onodera Y, Hashimoto A, Tanaka M, Hamaguchi M, Yamada A, et al. Requirement for Arf6 in breast cancer invasive activities. Proc Natl Acad Sci USA. 2004;101:6647–52.
Article CAS PubMed PubMed Central Google Scholar
Palacios F, Price L, Schweitzer J, Collard JG, D’Souza-Schorey C. An essential role for ARF6-regulated membrane traffic in adherens junction turnover and epithelial cell migration. EMBO J. 2001;20:4973–86.
Article CAS PubMed PubMed Central Google Scholar
Ratcliffe CDH, Siddiqui N, Coelho PP, Laterreur N, Cookey TN, Sonenberg N, et al. HGF-induced migration depends on the PI(3,4,5)P3-binding microexon-spliced variant of the Arf6 exchange factor cytohesin-1. J Cell Biol. 2019;218:285–98.
Article CAS PubMed PubMed Central Google Scholar
Furman C, Short SM, Subramanian RR, Zetter BR, Roberts TM. DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism. J Biol Chem. 2002;277:7962–9.
Article CAS PubMed Google Scholar
Sabe H, Hashimoto S, Morishige M, Ogawa E, Hashimoto A, Nam JM, et al. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis. Traffic. 2009;10:982–93.
Article CAS PubMed PubMed Central Google Scholar
Laurent C, Valet F, Planque N, Silveri L, Maacha S, Anezo O, et al. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 2011;71:666–74.
Article CAS PubMed Google Scholar
Ehlers JP, Worley L, Onken MD, Harbour JW. DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer Res. 2005;11:3609–13.
Article CAS PubMed Google Scholar
Li R, Peng C, Zhang X, Wu Y, Pan S, Xiao Y. Roles of Arf6 in cancer cell invasion, metastasis and proliferation. Life Sci. 2017;182:80–84.
Article CAS PubMed Google Scholar
Perrin L, Belova E, Bayarmagnai B, Tuzel E, Gligorijevic B. Invadopodia enable cooperative invasion and metastasis of breast cancer cells. Commun Biol. 2022;5:758.
Article CAS PubMed PubMed Central Google Scholar
Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205–9.
Article CAS PubMed PubMed Central Google Scholar
Onodera Y, Hashimoto S, Hashimoto A, Morishige M, Mazaki Y, Yamada A, et al. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. EMBO J. 2005;24:963–73.
Article CAS PubMed PubMed Central Google Scholar
Muller MR, Rao ANFAT. immunity and cancer: a transcription factor comes of age. Nat Rev Immunol. 2010;10:645–56.
Article PubMed Google Scholar
Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109:S67–79.
Article CAS PubMed Google Scholar
Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science. 1999;285:2129–33.
Article CAS PubMed Google Scholar
Noguchi H, Matsushita M, Okitsu T, Moriwaki A, Tomizawa K, Kang S, et al. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med. 2004;10:305–9.
Article CAS PubMed Google Scholar
Collaborative Ocular Melanoma Study G Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119:670–6.
Article Google Scholar
Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92.
Article CAS PubMed PubMed Central Google Scholar
Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16:201–18.
Article CAS PubMed PubMed Central Google Scholar
Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, et al. NFATc2 is a potential therapeutic target in human melanoma. J Invest Dermatol. 2012;132:2652–60.
Article CAS PubMed Google Scholar
Shoshan E, Braeuer RR, Kamiya T, Mobley AK, Huang L, Vasquez ME, et al. NFAT1 directly regulates IL8 and MMP3 to promote melanoma Tumor Growth and Metastasis. Cancer Res. 2016;76:3145–55.
Article CAS PubMed PubMed Central Google Scholar
Qin JJ, Nag S, Wang W, Zhou J, Zhang WD, Wang H, et al. NFAT as cancer target: mission possible? Biochim Biophys Acta. 2014;1846:297–311.
CAS PubMed PubMed Central Google Scholar
Grossmann AH, Yoo JH, Clancy J, Sorensen LK, Sedgwick A, Tong Z, et al. The small GTPase ARF6 stimulates beta-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Signal. 2013;6:ra14.
Article PubMed PubMed Central Google Scholar
Gabriel CH, Gross F, Karl M, Stephanowitz H, Hennig AF, Weber M, et al. Identification of novel nuclear factor of activated T cell (NFAT)-associated proteins in T cells. J Biol Chem. 2016;291:24172–87.
Article CAS PubMed PubMed Central Google Scholar
Britton S, Dernoncourt E, Delteil C, Froment C, Schiltz O, Salles B, et al. DNA damage triggers SAF-A and RNA biogenesis factors exclusion from chromatin coupled to R-loops removal. Nucleic Acids Res. 2014;42:9047–62.
Article CAS PubMed PubMed Central Google Scholar
Zhu W, London NR, Gibson CC, Davis CT, Tong Z, Sorensen LK, et al. Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability. Nature. 2012;492:252–5.
Article CAS PubMed PubMed Central Google Scholar
Onken MD, Worley LA, Person E, Char DH, Bowcock AM, Harbour JW. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res. 2007;13:2923–7.
Article CAS PubMed Google Scholar
Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12:461–8.
Article CAS PubMed PubMed Central Google Scholar
Download references
We thank D. Lim for graphics preparation. This research utilized both University of Utah and Huntsman Cancer Institute shared research resources including the Preclinical Research Resource, DNA Sequencing Core Facility, Bioinformatics Core Facility, and Fluorescence Microscopy Core Facility and was supported in part by the National Cancer Institute of the National Institutes of Health under Award Number P30CA042014. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
This study was supported by the National Cancer Institute R00CA230312 (JHY), the Department of Defense Melanoma Research Program ME190288 (JHY), the Melanoma Research Foundation 51005681 (JHY), the National Institute of General Medical Sciences COBRE P20GM121316 (JHY), F30CA217184 (JRR), F30CA235964 (AT) and R01CA202778 (SJO).
Jackson R. Richards
Present address: Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA
These authors contributed equally: Shannon J. Odelberg, Jae Hyuk Yoo.
Department of Oncological Sciences, School of Medicine, University of Utah, 2000 Circle of Hope Drive, Salt Lake City, UT, 84112, USA
Jackson R. Richards, Amanda Truong & Martin McMahon
Department of Medicine, Program in Molecular Medicine, University of Utah, 15 North 2030 East, Salt Lake City, UT, 84112, USA
Jackson R. Richards, Donghan Shin, Rob Pryor, Lise K. Sorensen, Zhonglou Sun, Weiquan Zhu & Shannon J. Odelberg
Department of Ophthalmology & Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, 68198, USA
Won Mi So, Garam Park & Jae Hyuk Yoo
Department of Pathology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT, 84112, USA
Roger Wolff & Allie H. Grossmann
Huntsman Cancer Institute, University of Utah Health Sciences Center, 2000 Circle of Hope Drive, Salt Lake City, UT, 84112, USA
Roger Wolff, Amanda Truong, Martin McMahon & Allie H. Grossmann
Department of Dermatology, University of Utah, 30 N 1900 E, Salt Lake City, UT, 84132, USA
Martin McMahon
ARUP Laboratories, University of Utah, 500 Chipeta Way, Salt Lake City, UT, 84112, USA
Allie H. Grossmann
Department of Ophthalmology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, 75390, USA
J. William Harbour
Division of Cardiovascular Medicine, Department of Medicine, University of Utah, 30 North 1900 East, Salt Lake City, UT, 84132, USA
Weiquan Zhu & Shannon J. Odelberg
Department of Neurobiology, University of Utah, 20 South 2030 East, Salt Lake City, UT, 84112, USA
Shannon J. Odelberg
Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA
Jae Hyuk Yoo
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
SJO and JHY were responsible for conceptualization, experimental design, data analysis, and manuscript preparation. JHY primarily performed and collected data for in vitro experiments. JRR and DS primarily performed and collected data for in vivo experiments. RP, ZS, WMS, GP, and AT performed in vitro/in vivo experiments. LKS performed immunocytofluorescent staining. RW performed bioinformatic analyses. AHG provided histology and pathology expertise. MM, AHG, JWH, and WZ provided resources and critical review of the manuscript. All authors read the manuscript, agree with the content, and were given the opportunity to provide input.
Correspondence to Shannon J. Odelberg or Jae Hyuk Yoo.
JWH is the inventor of intellectual property related to prognostic testing in uveal melanoma. He is a paid consultant for Castle Biosciences, licensee of this intellectual property, and he receives royalties from its commercialization.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
Richards, J.R., Shin, D., Pryor, R. et al. Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis. Oncogene 42, 2629–2640 (2023). https://doi.org/10.1038/s41388-023-02792-6
Download citation
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-023-02792-6
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
Advertisement
© 2024 Springer Nature Limited
About The Author
More Stories
Local Infrastructure, Lower Costs: How Peering Is Moving the Needle on Internet Affordability
On Global Accessibility Awareness Day, An Internet for Everyone Must Include Everyone
An Open Fiber Data Standard to Make the Internet for Everyone